NuVasive, Inc. Logo

NuVasive, Inc.

NUVA

(1.0)
Stock Price

39,75 USD

2.37% ROA

4.86% ROE

68.48x PER

Market Cap.

2.084.855.700,00 USD

101.52% DER

0% Yield

3.36% NPM

NuVasive, Inc. Stock Analysis

NuVasive, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

NuVasive, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE falls within an average range (3.28%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (2.22%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

3 PBV

The stock's PBV ratio (2.33x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

4 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (531) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

5 DER

The company has a high debt to equity ratio (102%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

NuVasive, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

NuVasive, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

NuVasive, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

NuVasive, Inc. Revenue
Year Revenue Growth
2000 52.000
2001 2.564.000 97.97%
2002 12.260.000 79.09%
2003 22.655.000 45.88%
2004 38.403.000 41.01%
2005 61.789.000 37.85%
2006 98.091.000 37.01%
2007 154.290.000 36.42%
2008 250.082.000 38.3%
2009 370.340.000 32.47%
2010 478.237.000 22.56%
2011 540.506.000 11.52%
2012 620.255.000 12.86%
2013 685.173.000 9.47%
2014 762.415.000 10.13%
2015 811.113.000 6%
2016 962.072.000 15.69%
2017 1.029.520.000 6.55%
2018 1.101.714.000 6.55%
2019 1.168.070.000 5.68%
2020 1.050.582.000 -11.18%
2021 1.138.988.000 7.76%
2022 1.201.942.000 5.24%
2023 1.271.144.000 5.44%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

NuVasive, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2000 9.011.000
2001 7.331.000 -22.92%
2002 6.107.000 -20.04%
2003 6.310.000 3.22%
2004 8.348.000 24.41%
2005 10.386.000 19.62%
2006 17.747.000 41.48%
2007 24.581.000 27.8%
2008 46.819.000 47.5%
2009 37.581.000 -24.58%
2010 43.479.000 13.57%
2011 40.703.000 -6.82%
2012 35.296.000 -15.32%
2013 32.209.000 -9.58%
2014 37.986.000 15.21%
2015 35.851.000 -5.96%
2016 47.999.000 25.31%
2017 50.425.000 4.81%
2018 61.695.000 18.27%
2019 72.380.000 14.76%
2020 79.838.000 9.34%
2021 92.626.000 13.81%
2022 98.524.000 5.99%
2023 114.616.000 14.04%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

NuVasive, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 8.584.000 100%
2005 16.867.000 49.11%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 575.836.000 100%
2019 0 0%
2020 0 0%
2021 0 0%
2022 634.095.000 100%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

NuVasive, Inc. EBITDA
Year EBITDA Growth
2000 -14.267.000
2001 -6.121.000 -133.08%
2002 -13.368.000 54.21%
2003 -8.323.000 -60.62%
2004 -12.286.000 32.26%
2005 -1.341.000 -816.18%
2006 -5.644.000 76.24%
2007 -4.300.000 -31.26%
2008 -4.755.000 9.57%
2009 42.665.000 111.14%
2010 69.587.000 38.69%
2011 71.400.000 2.54%
2012 100.575.000 29.01%
2013 100.052.000 -0.52%
2014 123.246.000 18.82%
2015 171.666.000 28.21%
2016 201.854.000 14.96%
2017 242.209.000 16.66%
2018 224.531.000 -7.87%
2019 252.640.000 11.13%
2020 175.747.000 -43.75%
2021 180.915.000 2.86%
2022 211.802.000 14.58%
2023 244.896.000 13.51%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

NuVasive, Inc. Gross Profit
Year Gross Profit Growth
2000 -35.000
2001 1.210.000 102.89%
2002 6.957.000 82.61%
2003 15.864.000 56.15%
2004 28.175.000 43.69%
2005 49.397.000 42.96%
2006 79.063.000 37.52%
2007 126.908.000 37.7%
2008 205.781.000 38.33%
2009 309.230.000 33.45%
2010 393.098.000 21.34%
2011 428.395.000 8.24%
2012 466.846.000 8.24%
2013 504.689.000 7.5%
2014 580.057.000 12.99%
2015 616.634.000 5.93%
2016 721.979.000 14.59%
2017 760.512.000 5.07%
2018 790.555.000 3.8%
2019 855.713.000 7.61%
2020 728.951.000 -17.39%
2021 816.710.000 10.75%
2022 865.435.000 5.63%
2023 913.244.000 5.24%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

NuVasive, Inc. Net Profit
Year Net Profit Growth
2000 -14.150.000
2001 -17.902.000 20.96%
2002 -15.110.000 -18.48%
2003 -10.127.000 -49.21%
2004 -14.210.000 28.73%
2005 -30.339.000 53.16%
2006 -47.910.000 36.68%
2007 -11.265.000 -325.3%
2008 -27.528.000 59.08%
2009 5.808.000 573.97%
2010 78.285.000 92.58%
2011 -69.849.000 212.08%
2012 3.144.000 2321.66%
2013 7.902.000 60.21%
2014 -16.720.000 147.26%
2015 66.291.000 125.22%
2016 37.147.000 -78.46%
2017 83.006.000 55.25%
2018 12.479.000 -565.17%
2019 65.234.000 80.87%
2020 -37.153.000 275.58%
2021 -64.086.000 42.03%
2022 40.407.000 258.6%
2023 29.456.000 -37.18%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

NuVasive, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 -20
2001 -23 17.39%
2002 -13 -76.92%
2003 -6 -116.67%
2004 -1 -500%
2005 -1 0%
2006 -1 0%
2007 0 0%
2008 -1 0%
2009 0 0%
2010 2 100%
2011 -2 200%
2012 0 0%
2013 0 0%
2014 0 0%
2015 1 100%
2016 1 0%
2017 2 100%
2018 0 0%
2019 1 100%
2020 -1 0%
2021 -1 100%
2022 1 0%
2023 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

NuVasive, Inc. Free Cashflow
Year Free Cashflow Growth
2002 -15.257.000
2003 -10.463.000 -45.82%
2004 -14.704.000 28.84%
2005 -32.530.000 54.8%
2006 -46.001.000 29.28%
2007 -25.290.000 -81.89%
2008 -44.797.000 43.55%
2009 13.541.000 430.82%
2010 19.981.000 32.23%
2011 9.595.000 -108.24%
2012 88.893.000 89.21%
2013 49.842.000 -78.35%
2014 57.124.000 12.75%
2015 -19.065.000 399.63%
2016 62.005.000 130.75%
2017 66.488.000 6.74%
2018 109.580.000 39.32%
2019 104.906.000 -4.46%
2020 76.322.000 -37.45%
2021 69.718.000 -9.47%
2022 29.691.000 -134.81%
2023 -495.000 6098.18%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

NuVasive, Inc. Operating Cashflow
Year Operating Cashflow Growth
2002 -13.998.000
2003 -7.622.000 -83.65%
2004 -8.565.000 11.01%
2005 -19.855.000 56.86%
2006 -25.605.000 22.46%
2007 -887.000 -2786.7%
2008 -5.002.000 82.27%
2009 46.419.000 110.78%
2010 65.827.000 29.48%
2011 62.965.000 -4.55%
2012 130.082.000 51.6%
2013 97.439.000 -33.5%
2014 115.548.000 15.67%
2015 88.727.000 -30.23%
2016 156.295.000 43.23%
2017 178.979.000 12.67%
2018 219.183.000 18.34%
2019 235.290.000 6.85%
2020 185.911.000 -26.56%
2021 182.174.000 -2.05%
2022 169.118.000 -7.72%
2023 36.517.000 -363.12%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

NuVasive, Inc. Capital Expenditure
Year Capital Expenditure Growth
2002 1.259.000
2003 2.841.000 55.68%
2004 6.139.000 53.72%
2005 12.675.000 51.57%
2006 20.396.000 37.86%
2007 24.403.000 16.42%
2008 39.795.000 38.68%
2009 32.878.000 -21.04%
2010 45.846.000 28.29%
2011 53.370.000 14.1%
2012 41.189.000 -29.57%
2013 47.597.000 13.46%
2014 58.424.000 18.53%
2015 107.792.000 45.8%
2016 94.290.000 -14.32%
2017 112.491.000 16.18%
2018 109.603.000 -2.63%
2019 130.384.000 15.94%
2020 109.589.000 -18.98%
2021 112.456.000 2.55%
2022 139.427.000 19.34%
2023 37.012.000 -276.71%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

NuVasive, Inc. Equity
Year Equity Growth
2000 -720.000
2002 9.384.000 107.67%
2003 10.070.000 6.81%
2004 71.397.000 85.9%
2005 58.136.000 -22.81%
2006 176.303.000 67.02%
2007 196.578.000 10.31%
2008 187.631.000 -4.77%
2009 309.851.000 39.44%
2010 446.232.000 30.56%
2011 504.750.000 11.59%
2012 547.578.000 7.82%
2013 604.878.000 9.47%
2014 648.358.000 6.71%
2015 702.202.000 7.67%
2016 700.524.000 -0.24%
2017 799.154.000 12.34%
2018 834.525.000 4.24%
2019 915.207.000 8.82%
2020 918.918.000 0.4%
2021 795.207.000 -15.56%
2022 868.890.000 8.48%
2023 892.543.000 2.65%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

NuVasive, Inc. Assets
Year Assets Growth
2000 4.660.000
2002 14.932.000 68.79%
2003 22.371.000 33.25%
2004 80.752.000 72.3%
2005 71.490.000 -12.96%
2006 196.184.000 63.56%
2007 225.687.000 13.07%
2008 487.406.000 53.7%
2009 653.764.000 25.45%
2010 802.029.000 18.49%
2011 1.123.562.000 28.62%
2012 1.163.785.000 3.46%
2013 1.179.568.000 1.34%
2014 1.343.459.000 12.2%
2015 1.289.649.000 -4.17%
2016 1.570.804.000 17.9%
2017 1.639.067.000 4.16%
2018 1.707.859.000 4.03%
2019 1.885.290.000 9.41%
2020 2.693.082.000 30%
2021 2.154.075.000 -25.02%
2022 2.224.505.000 3.17%
2023 2.089.550.000 -6.46%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

NuVasive, Inc. Liabilities
Year Liabilities Growth
2000 0
2002 5.548.000 100%
2003 12.301.000 54.9%
2004 9.355.000 -31.49%
2005 13.354.000 29.95%
2006 19.881.000 32.83%
2007 29.109.000 31.7%
2008 299.775.000 90.29%
2009 343.913.000 12.83%
2010 355.797.000 3.34%
2011 618.812.000 42.5%
2012 626.210.000 1.18%
2013 574.690.000 -8.96%
2014 695.101.000 17.32%
2015 587.447.000 -18.33%
2016 870.280.000 32.5%
2017 839.913.000 -3.62%
2018 873.334.000 3.83%
2019 970.083.000 9.97%
2020 1.774.164.000 45.32%
2021 1.358.868.000 -30.56%
2022 1.355.615.000 -0.24%
2023 1.197.007.000 -13.25%

NuVasive, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
17.76
Net Income per Share
0.58
Price to Earning Ratio
68.48x
Price To Sales Ratio
2.24x
POCF Ratio
24.44
PFCF Ratio
-108.54
Price to Book Ratio
2.33
EV to Sales
3.13
EV Over EBITDA
19.59
EV to Operating CashFlow
34.14
EV to FreeCashFlow
-151.51
Earnings Yield
0.01
FreeCashFlow Yield
-0.01
Market Cap
2,08 Bil.
Enterprise Value
2,91 Bil.
Graham Number
14.91
Graham NetNet
-14.1

Income Statement Metrics

Net Income per Share
0.58
Income Quality
2.8
ROE
0.03
Return On Assets
0.02
Return On Capital Employed
0.04
Net Income per EBT
0.77
EBT Per Ebit
0.81
Ebit per Revenue
0.05
Effective Tax Rate
0.23

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.72
Operating Profit Margin
0.05
Pretax Profit Margin
0.04
Net Profit Margin
0.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
1.63
Free CashFlow per Share
-0.37
Capex to Operating CashFlow
-1.23
Capex to Revenue
-0.11
Capex to Depreciation
-1.01
Return on Invested Capital
0.03
Return on Tangible Assets
0.02
Days Sales Outstanding
104.73
Days Payables Outstanding
162.65
Days of Inventory on Hand
480.24
Receivables Turnover
3.49
Payables Turnover
2.24
Inventory Turnover
0.76
Capex per Share
-1.99

Balance Sheet

Cash per Share
1,57
Book Value per Share
17,03
Tangible Book Value per Share
1.61
Shareholders Equity per Share
17.03
Interest Debt per Share
17.57
Debt to Equity
1.02
Debt to Assets
0.43
Net Debt to EBITDA
5.56
Current Ratio
1.25
Tangible Asset Value
0,08 Bil.
Net Current Asset Value
-0,47 Bil.
Invested Capital
1.02
Working Capital
0,15 Bil.
Intangibles to Total Assets
0.39
Average Receivables
0,26 Bil.
Average Payables
0,12 Bil.
Average Inventory
348375000
Debt to Market Cap
0.43

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

NuVasive, Inc. Dividends
Year Dividends Growth

NuVasive, Inc. Profile

About NuVasive, Inc.

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

CEO
Mr. J. Christopher Barry
Employee
3.000
Address
7475 Lusk Boulevard
San Diego, 92121

NuVasive, Inc. Executives & BODs

NuVasive, Inc. Executives & BODs
# Name Age
1 Ms. Lisa Pecora
Vice President & Head of Global Commercial Fin.
70
2 Mr. Frank Middeke
Managing Director of DACH
70
3 Ms. Aviva McPherron
Senior Vice President of Information Technology
70
4 Mr. Johnson Lai
Chief Information Officer
70
5 Mr. Marc Rosenbaum
Vice President, Corporation Controller & Chief Accounting Officer
70
6 Mr. J. Christopher Barry
Chief Executive Officer & Director
70
7 Mr. Matthew K. Harbaugh
Principal Accounting Officer, Chief Financial Officer & Executive Vice President
70
8 Mr. Dale A. Wolf
Senior Vice President of Global Operations
70
9 Mr. Nathaniel B. Sisitsky Esq.
Senior Vice President, Gen. Counsel & Corporation Sec.
70
10 Mr. Michael Farrington
Senior Vice President of People & Culture
70
11 Mr. Ryan Donahoe
Senior Vice President & Chief Technology Officer
70
12 Ms. Juliet C. Cunningham
Vice President of Investor Relations
70
13 Mr. Sean Freeman
Senior Vice President of Strategy & Corporation Devel.
70

NuVasive, Inc. Competitors

Glaukos Corporation Logo
Glaukos Corporation

GKOS

(0.5)
CONMED Corporation Logo
CONMED Corporation

CNMD

(1.5)
LivaNova PLC Logo
LivaNova PLC

LIVN

(2.2)
Masimo Corporation Logo
Masimo Corporation

MASI

(1.0)
Pulmonx Corporation Logo
Pulmonx Corporation

LUNG

(1.2)
SI-BONE, Inc. Logo
SI-BONE, Inc.

SIBN

(1.0)
Heska Corporation Logo
Heska Corporation

HSKA

(1.0)
Bruker Corporation Logo
Bruker Corporation

BRKR

(2.5)
Paragon 28, Inc. Logo
Paragon 28, Inc.

FNA

(1.5)
Nevro Corp. Logo
Nevro Corp.

NVRO

(1.0)